Takeda Pharmaceutical (TSE:4502) Launches ORZEYFUL, Is It Still 6% Undervalued?

Takeda Pharmaceutical (TSE:4502) has moved into the spotlight after launching ORZEYFUL in Japan and China for narcolepsy type 1. Investors now have a fresh product milestone to weigh against recent share performance.

ORZEYFUL’s launch comes on top of a strong run in Takeda Pharmaceutical’s shares. The latest ¥6,223 price follows a 6.5% 7-day share price return and a 26.6% year-to-date gain. The 1-year total shareholder return of 53.7% and 5-year total shareholder return of 140.8% point to momentum that has been building rather than fading, as new products and trial results like TAK-881 keep the pipeline in focus.

Capitalize on Takeda Pharmaceutical’s orexin breakthrough by scanning a curated set of late-stage healthcare and biotech opportunities in the 73 high quality undiscovered gems.

The recent surge in Takeda Pharmaceutical's share price reflects excitement around ORZEYFUL and the broader orexin platform. After such a strong run, investors may now be assessing whether the current valuation offers sufficient potential reward relative to the risks involved.

Most Popular Narrative: 6% Undervalued

Taken against the most followed fair value estimate of ¥6,622, Takeda Pharmaceutical’s last close at ¥6,223 leaves a modest gap that rests on whether the orexin and immune pipelines can offset older portfolio pressures.

The key requirement for this view is successful execution on the FY26 growth investment phase, including timely and well supported launches of the orexin and TYK2 franchises, as well as continued delivery of cost and efficiency gains from AI enabled R&D and regulatory processes, while managing ENTYVIO biosimilar and other loss of exclusivity pressures.

See why 17 investors see Takeda Pharmaceutical as 6% undervalued.

Result: Fair Value of ¥6,622 (UNDERVALUED)

Still, the story around Takeda Pharmaceutical can change quickly if ENTYVIO biosimilar competition intensifies or if newer launches underperform current analyst expectations.

Find out about the key risks to this Takeda Pharmaceutical narrative.

Next Steps

Opinions are mixed on whether the optimism around Takeda Pharmaceutical outweighs the concerns. Move quickly, review the data for yourself, then weigh up the 2 key rewards and 2 important warning signs.

Looking for more Takeda Pharmaceutical sized ideas?

If you like how Takeda Pharmaceutical blends clear catalysts with defined risks, do not stop here. Broaden your watchlist with a few focused stock idea sets that match specific goals, so you are not relying on one story alone.

• Target reliable income potential by scanning companies that show resilient payouts and financial backing through the 29 dividend fortresses.
• Hunt for mispriced quality by reviewing the 14 high quality undervalued stocks and see which businesses combine solid fundamentals with room for a better market opinion.
• Lock in peace of mind by filtering for resilience first using the 22 resilient stocks with low risk scores, so short term swings do not dominate your portfolio decisions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com